Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057

… advanced, non-squamous (NSQ) non-small cell lung cancer (NSCLC). Opdivo continued to demonstrate … cell lung cancer support the potential for this Immuno-Oncology agent in treating lung cancer …  (5%) than docetaxel (15%). About Lung Cancer Lung cancer is the leading cause of …